Brief: Teva And Medincell’S Risperidone Lai Approved In Canada As Longavo®
23/09/2025 17:02
Sept 23 (Reuters) - Medincell SA MEDCL.PA: TEVA AND MEDINCELL’S RISPERIDONE LAI APPROVED IN CANADA AS LONGAVO® Source text: nBw2BQ2G7a Further company coverage: MEDCL.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Medincell SA
See all newsBrief: Medincell Has Secured An Additional EUR 13.8 Million In Non-Dilutive Financing From Leading European Commercial Banks And Bpifrance
Teva gains after FDA approves monthly schizophrenia injection
Corrected: UPDATE 1-Teva wins FDA approval for monthly schizophrenia injection Weltruza
Teva wins FDA approval for monthly schizophrenia injection Weltruza
Brief: Medincell Announces Temporary Shares Trading Suspension On Euronext Paris